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Background: Treatment of HIV infection in adolescents is challenging due to long duration of therapy and poor
adherence. Recently, the integrase strand transfer inhibitor dolutegravir (DTG) has been approved for the use in
adolescents with HIV, but evidence in clinical practice is very limited.
Methods: We describe six cases of HIV-infected children/adolescents successfully treated with DTG-based regimen.
Data relative to children/adolescents managed at the Referral Center for Pediatric HIV/AIDS of the University of
Naples were reviewed. Patients were tested before introduction of DTG, after 1 month and every 3 months in the
first 2 years to assess virologic and immunological response, tolerance and development of side effects. Families
were asked to report any suspected adverse events.
Results: Six patients (2 male, median age 17 years, range 12–18) were started on DTG-based anti-retroviral regimen
due to low adherence to anti-retroviral treatment (ART), multiple drug resistance mutations, or development of
ART-related side effects. Within 4–8 weeks after DTG treatment onset, a complete viral suppression and a
concomitant increase of CD4+ cell count was observed. Four patients showed a persistent suppression after 2 years
of follow-up, and 2 patients at about 1 year. One month after the introduction of DTG, the patient enrolled because
of severe dyslipidaemia and hyper-transaminasemia showed a complete normalization of laboratory values. During
follow-up (median 24 months, range 9–24) no adverse events were reported and most patients demonstrated a
good adherence to treatment.
Conclusions: DTG-based treatments demonstrated efficacy and good safety profile in adolescents. All patients
demonstrated a rapid virologic and immunological response within 4–8 weeks, with good adherence and absence
of side effects.
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The treatment of adolescents with vertically-acquired HIV
infection is particularly challenging [1] due to social and
clinical factors. Poor adherence to long-term anti-retroviral
therapy (ART), and consequent treatment failure with mul-
tiple therapy shifts, have been reported in adolescents with
HIV infection. This condition could be related to multiple* Correspondence: alfguari@unina.it
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covery of sexuality and acceptance of HIV-related “stigma”,
the limited awareness of infection state and a general misin-
formation about HIV infection, often associated with socio-
economically deprived communities [2, 3].
Several studies have identified both pill burden and life-
style issues (i.e., not having medications on hand when
away from home, changes in schedule) as major barriers
to effective adherence. Choosing the simplest regimen
possible, reducing dose frequency and pill number and
selecting a regimen that fits well to daily patients and fam-
ily activities, are important strategies to achieve.le is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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have been approved as preferred regimens for treating chil-
dren and adolescents with HIV infection [4, 5]. Dolutegravir
(DTG) has interesting pharmacokinetic/pharmacodynamic
features such as prolonged intracellular half-life, absence of
negative interactions with other anti-retroviral drugs and a
potent activity against HIV-1 strains that are resistant to
other INSTIs [6]. Its use is currently approved for treatment
of HIV-infected adolescents (> 12 years old and/or above
40 kg of weight) [4, 5]. The approval was supported by data
from a study of 23 treatment-experienced but INSTI-naive
children and adolescents [7]. The drug has a very favourable
safety profile and can be administered once a day to INSTI-
naive patients [8]. These characteristics made DTG highly
suitable for adolescents infected with HIV strains resistant
to other anti-retroviral drugs.
Recently DTG, in combination with other anti-retroviral
drugs, was effective in dramatically reducing viral replica-
tion without side effects in two patients, an adult [9] and a
child [10], both with multidrug genetic resistance profile,
and has been used to prevent mother-to-child HIV trans-
mission [11].
Methods
We performed a retrospective review of adolescents with
HIV infection treated with DTG at the Regional Referral
Center for Pediatric HIV of the University of Naples Feder-
ico II in collaboration with consultants from the Unit of
Viral Diseases. Clinical and laboratory data were retrieved
through manual chart reviewing. All patients aged ≤
18 years old were tested before ARTswitch (T0), at 1 month
(T1), and successively every 3 months after introduction of
new ART regimen to assess virologic and immunological
response and the potential development of side-effects.
Viral load was evaluated by using a real time-PCR (Ab-
bott, with cut off sensitivity 40 copies/ml and dynamic
range 40–1.000.000 copies/ml). Caregivers of children
were required to report any suspect adverse event to the
Reference Center after ART switch. Other potential side
effects were specifically looked for during follow-up visits.
DTG was prescribed according to recent guidelines for
the management of HIV infection in children and adoles-
cent [4, 5].
No ethical committee opinion was requested because
the use of this drug in adolescents is suggested by inter-
national guidelines. All procedures performed in this
study were in accordance with the 1964 Helsinki declar-
ation and its later amendments or comparable ethical
standards. An informed consent for sharing anonymous
patient data was obtained from families and/or care-
givers. All drugs were provided by the University Hos-
pital Pharmacy and paid by the National Health Care
System according to Italian legislation. No direct contact
with drug companies was taken.Results
Dolutegravir-based therapy onset
Since January 2015 a DTG-based ART was prescribed to
6 paediatric patients (2 males, median age 17 years,
range 12–18) due to previous treatment failure, develop-
ment of side effects, presence of multiple viral resistance
or low adherence to ART (Tables 1 and 2). An additional
patient receiving a DTG-based regimen was excluded
from the present study due to the lack of data after the
first month of prescription (lost to follow-up).
All but one patients were classified as stage 3 accord-
ing to the 2014 Center for Disease Control and Preven-
tion (CDC) Classification for paediatric HIV/AIDS [12]
and none of them presented AIDS-defining conditions.
The clinical management of patient 1 and patient 2,
both female in stage 3, was complicated by missed medical
visits, a sustained low compliance to ART and the devel-
opment of multiple genetic resistance mutations. They re-
ceived various anti-retroviral drugs combined in different
regimens: zidovudine (ZDV), stavudine (D4T), lamivudine
(3TC), efavirenz (EFV), nelfinavir (NFV), lopinavir/ritona-
vir (LPV/r), tenofovir (TDF), emtricitabine (FTC).
The last ART regimen was LPV/r and TDF/FTC, which
was poorly tolerated due to persistent gastrointestinal side
effects in both patients. Particularly, although other alter-
native regimens including PI were considered, patient 1
experienced severe and frequent side effects related to PI,
with recurrent abdominal and epigastric pain, nausea, epi-
sodes of vomiting and anorexia. Because of the persistence
of virologic failure associated with a decrease of CD4+
cells, on January 2015, a once-daily regimen with DTG
and TDF/FTC was started with the aim of increasing
compliance and immunological and virologic response.
Patient 3 was a 12-year-old male admitted to our Depart-
ment for acute pancreatitis whose mother died 8 years be-
fore due to AIDS-related meningitis, and he never
underwent testing because of parental refusal. At the time
of HIV diagnosis, he presented with 190 CD4+ cells/μl (8%)
with a viral load of 19.800 copies/ml. Since the patient was
naïve to anti-retroviral therapy, we started anti-retroviral
treatment with LPV/r and ABC plus 3TC, according to
Pediatric Guidelines for HIV infection [5]. After 4 weeks of
treatment a good virologic response was obtained with a
substantial reduction of HIV viral load (from 19.800 to 191
copies/ml, 2 logs in 4 weeks). However, after one month of
LPV/r-based ART, the patient showed a sustained increase
of total cholesterol (749 mg/dl), LDL cholesterol (513 mg/
dl) and serum triglycerides (345 mg/dl), with concomitant
reduction of HDL cholesterol (5 mg/dl). Dyslipidaemia was
associated with hyper-transaminasemia (AST and ALT > 5
times normal values) and an increase in alkaline phosphat-
ase (1774 mg/dl). Considering child age, the expected long
duration of therapy and the elevated risk of persistent hyper-
cholesterolemia and hyper-triglyceridemia associated to
Table 1 Description of the patients involved in the study
Patient Gender Age Country of
origin


















3 M 12 Italy 3 LPV/r +
ABC + 3TC
DTG/ABC/3TC Side effects 24
4 M 16 Italy 1 LPV/r + TDF/FTC DTG + TDF/FTC Side effects
Low adherence
24
5 F 18 Nigeria 3 FPV + TDF/FTC + ATV + RTV DTG + TDF/FTC ART simplification 12
6 F 17 Ukraine 3 EFV + FTC + TDF DTG/ABC/3TC Side effects
Low adherence
9
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to a DTG-based regimen (DTG+ABC+ 3TC) (Table 1).
Patient 4 was a 16-year-old Italian male who was on
LPV/r + TDF/FTC in the last 4 years of follow-up, and
subsequently developed chronic (not infectious) diar-
rhoea as side effect of ART. This was responsible for a
progressive decrease in treatment adherence and he was
switched to DTG-based regimen.
Patient 5 was an 18-year-old female treated with FPV
+ TDF/FTC + ATV + RTV due to a complex mutation
profile. A DTG-based regimen was introduced in order
to simplify the ART.
Patient 6 was a 17-year-old female from Ukraine
treated with EFV + FTC + TDF. In order to improve
compliance, a DTG-based regimen was started.
Viro-immunological response
Patients 1, 3 and 4 experienced full viral suppression
(HIV viral load < 40 copies/ml) within the first 4 weeks.
Patient 2 demonstrated a significative reduction (2 logs)
after 4 weeks and a complete viral suppression after
8 weeks of treatment. Patients 5 and 6, who already hadTable 2 Mutations and resistance pattern
Patient Reverse transcriptase
Mutations Resistance
1 M41 L, V75IMV, F77 L,
T215D, E44A/D, V118I,
D67N, M184 V
3TC (LR), ABC (IR), ZDV (HR), D4T (HR),
(HR), FTC (LR), TDF (IR), EFV (S), ETR (S),
(S), RPV (S)
2 K103 N, P225H, M184 V 3TC (HR), ABC (LR), ZDV (S), D4T (S), DD
FTC (HR), TDF (S), EFV (HR), ETR (S), NVP
RPV (S)
3 Not available Not available
4 M184 V, G190A 3TC (HR), ABC (S), ZDV (S), D4T (S), DDI
FTC (HR), TDF (S), EFV (IR), NVP (HR)
5 D67N, K101P, K103 N/S,
M184 V, G190A, T215Y
3TC (HR), ABC (IR), ZDV (IR), D4T (IR), D
FTC (HR), TDF (S), EFV (HR), NVP (HR)
6 Not available Not availableundetectable viral load under previous ART regimen,
maintained a suppressed HIV load after treatment
switch (Fig. 1 a).
During follow-up, two patients (1 and 2), discontinued
ART and required unscheduled clinical visits that
showed viral load peaks of 1779 copies/ml (patient 1)
and 4100 copies/ml (patient 2). After discussions with
both patients regarding the importance of adherence
and the risks of acquiring further drug resistance muta-
tions, we observed virologic suppression at subsequent
visits, resulting from improved adherence to ART and
rapid response to DTG-based ART.
A progressive increase in CD4+ cells was observed in
all but one patients (Fig. 1 b).
Patient 3, who showed a major reduction in viral load
during LPV/r-based regimen, demonstrated full viral
suppression (HIV viral load < 40 copies/ml) and an in-
crease in CD4+ cells after three weeks of DTG-based
treatment (Fig. 1 a/b).
Patient 5, who was started on DTG-based regimen
with a high percentage of CD4+, had a slight reduc-




A71AV, N88DN, D30N LPV (S), ATV (LR), DRV (S), IDV (S),




K20I, A71AT, L89 V, M36I LPV (S), ATV (S), DRV (S), IDV (S),
FPV (S), NFV (LR), SQV (S), TPV (S)
Not available Not available
(S), L10 V, L63P LPV (S), ATV (S), DRV (S), IDV (S),
FPV (S), NFV (S), SQV (S), TPV (S)
DI (S), L10F, I13V, K20I, M36I, M46I,
Q58E, L63P, H69K, L76 V,
I84V, L89I
LPV (IR), ATV (HR), DRV (S), IDV
(IR), FPV (HR), NFV (HR), SQV (IR),
TPV (IR)
Not available Not available
ab
Fig. 1 a Effects of dolutegravir-based regimen on viral load after the
introduction of DTG-based regimen in 7 HIV-infected adolescents. b
Effects of dolutegravir-based regimen on CD4+ cell percentage after
the introduction of DTG-based regimen in 7 HIV-infected adolescents
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cyte count) and then remained substantially stable.
Follow-up and safety
The 6 patients were followed during the last two years with
a median follow-up of 24 months (range 9–24 months). All
patients are still in follow-up at our institution and DTG-
based treatment is still ongoing. Neither side effects or treat-
ment failure were observed during follow-up visits. Two
patients reported a transient reduction in ARTadherence.
Patient 3, who received DTG-based regimen due to the
presence of serious side effects, had a complete
normalization of total (142 mg/dl) and LDL (80 mg/dl)
cholesterol, triglycerides (74 mg/dl) concentrations and liver
markers (AST 36 U/ml, ALT 36 U/ml, ALP 263 mg/dl)
within one month after ART switch.
Discussion
Despite excellent efficacy, safety and tolerability in
adults, the effects of DTG in children and adolescentsare poorly documented. DTG is approved for patients ≥
12 years of age (recently anticipated at 6 years) and the
IMPAACT study showed that 70% of adolescents (12 to
< 18 years old) treated with DTG achieve a complete
viral suppression [8]. Data from literature demonstrated
that DTG is useful as a rescue drug in the setting of pa-
tients with multi-drug resistance [13].
In our experience, two patients who in the last five years
never achieved a viral suppression with several ART regi-
mens, showed a rapid and good response to DTG-based
regimen. Both experienced a viral suppression and in-
crease of CD4+ cells, although their adherence to ART
was not optimal as demonstrated by a temporary viremia
relapse. As reported in adult patients [14], due to its high
genetic barrier, DTG may reduce the risk of developing
viral resistance also in poorly compliant adolescents.
Patient 3, the only one receiving DTG-based regimen for
serious ART-related side effects, reached a complete
normalization of dyslipidaemia and hyper-transaminasemia,
in association with a complete viral suppression, as previ-
ously reported in a large adult population [15]. The dra-
matic response of both viral load and CD4+ count, in
association with the normalization of lipid profile, suggests
that DTG-base regimen is a good therapeutic option also in
naïve HIV-infected adolescents.
One limitation of this study is that drug resistance
profiles were available for 4 of 6 patients. In adult
patients, DTG monotherapy is associated with an in-
creased risk of virological failure and DTG resistance
[16]. Further, while dual therapy with DTG + 3TC is
promising among adults, this study only included pa-
tients who were virologically suppressed at the time
of switch [17]. Finally, while DTG-based ART is su-
perior to LPV/r-based ART as a second-line therapy
in the DAWNING trial, patients in this cohort were
required to have at least 1 fully active NRTI [18].
Thus, for children who have high viral loads at the
time of switch in combination with extensive drug
resistance, the efficacy of DTG-based ART remains
unknown. In this cohort of children, 4 of 6 patients
had high viral loads at switch and at least one (pa-
tient 1) did not have any fully susceptible NRTI (al-
though in addition to TAMs, M184 V was present
which increases susceptibility to TDF). Thus in ap-
plying these findings to other cohorts of children,
one must carefully consider the baseline NRTI resist-
ance profile, as this may impact the long-term suc-
cess of this regimen.
Conclusions
In conclusion, this small size series indicates that
children and adolescents may benefit from DTG-
based regimen achieving a complete control of HIV
infection with no side effects. The major advantages
Bruzzese et al. Italian Journal of Pediatrics  (2018) 44:37 Page 5 of 5of DTG-based regimen are the possibility to reduce
the pill burden to two pills once a day, the increas-
ing treatment adherence and the low or absent risk
of additional drug resistance mutations. Good safety
profile was observed up to a maximum of 24 months
in our patients.
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